...
首页> 外文期刊>Journal of proteome research >Search for potential markers for prostate cancer diagnosis, prognosis and treatment in clinical tissue specimens using amine-specific isobaric tagging (iTRAQ) with two-dimensional liquid chromatography and tandem mass spectrometry
【24h】

Search for potential markers for prostate cancer diagnosis, prognosis and treatment in clinical tissue specimens using amine-specific isobaric tagging (iTRAQ) with two-dimensional liquid chromatography and tandem mass spectrometry

机译:使用二维液相色谱和串联质谱的胺特异性等压标记(iTRAQ),寻找可用于临床组织标本中前列腺癌的诊断,预后和治疗的潜在标志物

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

This study aimed to identify candidate new diagnosis and prognosis markers and medicinal targets of prostate cancer (PCa), using state of the art proteomics. A total of 20 prostate tissue specimens from 10 patients with benign prostatic hyperplasia (BPH) and 10 with PCa (Tumour Node Metastasis [TNM] stage T1-T3) were analyzed by isobaric stable isotope labeling (iTRAQ) and two-dimensional liquid chromatography-tandem mass spectrometry (2DLC-MS/MS) approaches using a hybrid quadrupole time-of-flight system (QqTOF). The study resulted in the reproducible identification of 825 nonredundant gene products (p <= 0.05) of which 30 exhibited up-regulation (>= 2-fold) and another 35 exhibited downregulation (<= 0.5-fold) between the BPH and PCa specimens constituting a major contribution toward their global proteomic assessment. Selected findings were confirmed by immunohistochemical analysis of prostate tissue specimens. The proteins determined support existing knowledge and uncover novel and promising PCa biomarkers. The PCa proteome found can serve as a useful aid for the identification of improved diagnostic and prognostic markers and ultimately novel chemopreventive and therapeutic targets.
机译:这项研究旨在使用最先进的蛋白质组学技术,确定候选的新诊断和预后标志物以及前列腺癌(PCa)的药物靶标。通过等压稳定同位素标记(iTRAQ)和二维液相色谱分析了10例良性前列腺增生(BPH)和10例PCa(肿瘤淋巴结转移[TNM] T1-T3期)患者的20个前列腺组织标本,串联质谱(2DLC-MS / MS)方法使用混合四极杆飞行时间系统(QqTOF)。该研究可重现BPH和PCa标本中的825种非冗余基因产物(p <= 0.05),其中30种表现出上调(> = 2倍),另外35种表现出下调(<= 0.5倍)为他们的全球蛋白质组学评估做出了重要贡献。通过对前列腺组织标本的免疫组织化学分析证实了所选的发现。确定的蛋白质支持现有知识,并揭示了新颖而有前途的PCa生物标志物。发现的PCa蛋白质组可以用作鉴定改良的诊断和预后标志物以及最终新颖的化学预防和治疗靶标的有用帮助。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号